Study:
Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Liver Transplant Recipients
Rationale:
n/a
Purpose:
The main focus of this study is to develop blood and/or urine tests that will help to detect
early signs of rejection in people who have had a liver transplant. Researchers will examine
blood, urine, and tissue samples and try to identify markers for certain conditions such as
rejection, response to therapy, and scarring of the liver. Additionally, researchers would
like to identify biomarkers that can detect damage to the native kidneys before blood levels
of creatinine rises. By studying gene expression, researchers hope to be able to diagnose
these conditions earlier and improve liver survival.
Study Status: Not yet recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Proteogenomic Monitoring in Liver Transplant Recipients |
n/a |
N/A |
Verified by
National Institute of Allergy and Infectious Diseases (NIAID)
August, 2012
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov identifier: NCT01672164
Study Type: Interventional
Study Design: Observational Model: Cohort, Time Perspective: Prospective
Cleveland Clinic Foundation
Cleveland, Ohio 44295
United States
Josh Levitsky, MD, MS., Study Chair
MICHAEL ABECASSIS, MD, MBA., Principal Investigator